HANGZHOU TIGERMED CONSULTING (300347) H2 2025 earnings summary

Executive summary

• 2025 marked a pivotal year with steady growth in the global biopharmaceutical industry, driven by aging populations, chronic disease management, and technological breakthroughs.

• The company achieved RMB6.83 billion in revenue, supported R&D for 49 marketed Class 1 innovative drugs, and maintained a leading industry position.

• Global expansion continued, with significant growth in overseas clinical business and workforce, especially in North America, Japan, India, and Malaysia.

• Digitalization and AI strategies advanced, with commercial deployment of proprietary platforms improving efficiency and compliance.

Financial highlights

• Revenue increased 3.5% YoY to RMB6,832.8 million; net profit attributable to owners rose 119.2% YoY to RMB887.9 million.

• Gross profit margin declined to 27.4% from 34.0% YoY; net profit margin improved to 13.0% from 6.1%.

• Basic and diluted EPS were RMB1.04, up from RMB0.47 YoY.

• Total assets stood at RMB28,358.8 million; equity attributable to owners was RMB20,959.5 million.

• Net cash from operating activities was RMB1,118.1 million, up 1.9% YoY.

Outlook and guidance

• Industry recovery and increased client demand are expected to drive further growth in 2026, with a focus on expanding global delivery and digital capabilities.

• The company will continue to invest in AI, digital platforms, and M&A opportunities, aiming for quality and efficiency improvements.

• Strategic partnerships and global expansion remain priorities, with a focus on sustainable business development and shareholder value.